Address correspondence to Dr Jeffrey Allen, Department of Neurology, 12-150 PWB, MMC 295, 516 Delaware St SE, Minneapolis, MN 55455, [email protected].
Relationship Disclosure: Dr Allen serves on the global medical advisory board of the GBC/CIDP Foundation International, on the organizing committee of the Inflammatory Neuropathy Consortium, and as a consultant for CSL Behring and Grifols. Dr Allen receives research/grant support from CSL Behring and has received personal compensation for speaking engagements from Grifols.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Allen discusses the unlabeled/investigational use of alemtuzumab, azathioprine, bevacizumab, chlorambucil, cyclophosphamide, cyclosporine, fludarabine, interferon beta-1a, lenalidomide, melphalan, methotrexate, mycophenolate mofetil, rituximab, tacrolimus, and thalidomide for the treatment of chronic demyelinating polyneuropathies.